Sotagliflozin + Placebo
Phase 3Recruiting 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Cardiomyopathy, Hypertrophic
Conditions
Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Trial Timeline
Sep 24, 2024 โ Aug 1, 2026
NCT ID
NCT06481891About Sotagliflozin + Placebo
Sotagliflozin + Placebo is a phase 3 stage product being developed by Lexicon Pharmaceuticals for Obstructive Cardiomyopathy, Hypertrophic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06481891. Target conditions include Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06435156 | Phase 2 | Recruiting |
| NCT06481891 | Phase 3 | Recruiting |
Competing Products
20 competing products in Obstructive Cardiomyopathy, Hypertrophic